natgillin/translations-raw huggingface dataset:
One controlled clinical trial with Betaferon was performed in patients with a single clinical event and MRI features suggestive of multiple sclerosis (at least two clinically silent lesions on the T2-weighted MRI).
Pri bolnikih z enim samim kliničnim dogodkom in izvidi magnetnoresonančnega slikanja, ki kažejo na multiplo sklerozo (vsaj dve klinično tihi leziji na T2-poudarjenem magnetnoresonančnem slikanju) so izvedli nadzorovano klinično preskušanje.
One controlled clinical trial with Extavia was performed in patients with a single clinical event and Magnetic Resonance Imaging (MRI) features suggestive of multiple sclerosis (at least two clinically silent lesions on the T2-weighted MRI).
Pri bolnikih z enim samim kliničnim dogodkom in izvidi magnetno resonančnega slikanja (MRI - Magnetic Resonance Imaging), ki kažejo na multiplo sklerozo (vsaj dve klinično tihi leziji na T2- poudarjenem magnetnoresonančnem slikanju) so opravili kontrolirano klinično preskušanje.
One cotton ball or gauze
Eno vato ali gazo.
One cutaneous patch
en dermalni obliž
One dose (0.2 ml) contains:
En odmerek (0,2 ml) vsebuje:
One dose (0.5 ml of the reconstituted vaccine) contains: (Originally contained in the powder)
En odmerek (0,5 ml rekonstituiranega cepiva) vsebuje: (Originalno vsebovano v prašku)
One dose (0.5 ml of the reconstituted vaccine) contains: The active substances are:
En odmerek (0,5 ml rekonstituiranega cepiva) vsebuje: Zdravilne učinkovine so:
One dose (0.5 ml) contains: Active Ingredients: Influenza virus surface antigens (haemagglutinin and neuraminidase), propagated in eggs, and adjuvanted with MF59C.1, of strain:
En odmerek (0,5 ml) vsebuje: Zdravilne učinkovine: površinski antigeni (hemaglutinin in nevraminidaza), razmnoženi v jajcih, z dodanim adjuvansom MF59C.1, seva virusa influence:
One dose (0.5 ml) contains: Active Ingredients: Influenza virus surface antigens (haemagglutinin and neuraminidase), propagated in eggs, and adjuvanted with MF59C.1, of strain:
En odmerek (0,5 ml) vsebuje: Zdravilne učinkovine: površinski antigeni (hemaglutinin in nevraminidaza), razmnoženi v jajcih, z dodanim adjuvansom MF59C.1, seva virusa influenze:
One dose (1 ml) contains:
En odmerek (1 ml) vsebuje:
One dose (1 ml) contains:
Odmerek (1 ml) vsebuje:
One dose is
en odmerek je
One dose is
en odmerek je:
One dose of 0.5 ml contains: Active Ingredients: Influenza virus surface antigens (haemagglutinin and neuraminidase), propagated in eggs, and adjuvanted with MF59C.1, of strain:
En odmerek z 0,5 ml vsebuje: Zdravilne učinkovine: površinski antigeni (hemaglutinin in nevraminidaza), razmnoženi v jajcih, z dodanim adjuvansom MF59C.1, seva:
One dose of 0.5 ml contains: Active Ingredients: Influenza virus surface antigens (haemagglutinin and neuraminidase), propagated in eggs, of strain:
En odmerek (0,5 ml) vsebuje: Zdravilna učinkovina: površinski antigeni (hemaglutinin in nevraminidaza) virusa influence, razmnoţen v jajcih, seva:
One dose of 0.5 ml will be given.
Daje se en odmerek po 0,5 ml.
One dose of 0.5ml contains:
En odmerek po 0,5 ml vsebuje:
One dose of 1 ml contains:
En odmerek (1ml) vsebuje:
One dose of 2 ml contains:
1 odmerek (2 ml) vsebuje:
One dose of 2 ml contains:
En 2 ml odmerek vsebuje:
One dose of 2 ml contains:
En odmerek po 2 vsebuje:
One dose of 2 ml of vaccine contains:
En 2 ml odmerek vsebuje:
One dose of 2 ml of vaccine contains:
Vsak odmerek cepiva (2 ml) vsebuje:
One dose of 2 ml: Inactivated bluetongue virus, serotype 8, strain BTV-8/BEL2006/02
En 2 ml odmerek: Inaktiviran virus modrega jezika, serotip 8, sev BTV-8/BEL2006/02
One dose of 30 l to be administered by eye drop.
En odmerek 30 l se da kot kapljica v oko.
One dose of 30l should be administered by eye drop.
En odmerek 30 l se da kot kapljica v oko.
One dose of AS03-adjuvanted vaccine containing 3.75 µg HA derived from A/Indonesia/05/2005 manufactured using a different process administered after one or two doses of AS03-adjuvanted vaccine containing 3.75 µg HA derived from A/Vietnam/1194/2004 manufactured using a different process
En odmerek cepiva z adjuvansom AS03 z vsebnostjo 3,75 µg HA iz A/Indonesia/05/2005, izdelanega po drugačnem postopku, uporabljen po enem ali dveh odmerkih cepiva z adjuvansom AS03 z vsebnostjo 3,75 µg HA iz A/Vietnam/1194/2004, izdelanega po drugačnem postopku
One dose of PecFent may include administration of 1 spray (100 microgram or 400 microgram doses) or 2 sprays (200 microgram or 800 microgram doses) of the same strength (either 100 microgram or 400 microgram strength).
En odmerek zdravila PecFent lahko pomeni uporabo 1 vpiha (100-mikrogramski ali 400- mikrogramski odmerek) ali 2 vpihov (200-mikrogramski ali 800-mikrogramski odmerek) iste jakosti (bodisi 100-mikrogramska bodisi 400-mikrogramska jakost).
One dose should be given yearly.
En odmerek letno.
One dose should be taken in the morning and one dose should be taken in the evening.
Bolnik naj vzame en odmerek zdravila zjutraj in enega zvečer.
One dose step contains 1 unit insulin degludec + 0.036 mg liraglutide.
En odmerni korak vsebuje 1 enoto insulina degludek + 0,036 mg liraglutida.
One dose, of 0.2 ml of reconstituted vaccine at least 72 hours prior to period of anticipated risk.
En odmerek po 0,2 ml rekonstituiranega cepiva najmanj 72 ur pred obdobjem povečane nevarnosti okužbe
One dose, of 0.2 ml of reconstituted vaccine at least 72 hours prior to period of anticipated risk.
En odmerek po 0,2 ml rekonstituiranega cepiva najmanj 72 ur pred obdobjem povečane nevarnosti okužbe.
One dose1 (0.5 ml) contains:
En odmerek1 (0,5 ml) vsebuje:
One drop containing one dose should be applied into one nostril or one eye.
Eno kapljico, ki vsebuje en odmerek, je treba dati v eno nosnico ali eno oko.
One drop in the affected eye or eyes, once a day-in the evening.
Ena kapljica v prizadeto oko ali oči, enkrat na dan - zvečer.
One drop in the affected eye or eyes, once a day-in the morning or in the evening.
ena kapljica v prizadeto oko ali obe očesi, enkrat na dan - zjutraj ali zvečer.
One drop in the affected eye or eyes, three times a day - morning, midday, and evening.
Ena kapljica v prizadeto oko ali očesi, trikrat na dan – zjutraj, opoldan in zvečer.
one drop in the affected eye or eyes, twice a day.
ena kapljica v prizadeto oko ali očesi dvakrat na dan.
One emergency kit contains 10 vials of Savene powder and 3 bottles of Savene diluent
En komplet za nujno uporabo vsebuje 10 vial praška Savene in 3 steklenice vehikla Savene.
One Enurev Breezhaler pack contains: one Enurev Breezhaler inhaler one or more blisters, each containing either 6 or 10 Enurev Breezhaler capsules to be used in the inhaler.
Vsako pakiranje zdravila Enurev Breezhaler vsebuje: en inhalator Enurev Breezhaler, en ali več pretisnih omotov, vsak vsebuje 6 ali 10 kapsul zdravila Enurev Breezhaler ki jih vstavljate v inhalator.
One epidemiological study suggested an increased risk of acute coronary syndrome in repaglinide treated patients as compared to sulfonylurea treated patients (see sections 4.4 and 4.8).
Ena epidemiološka študija je nakazala večje tveganje za akutni koronarni sindrom pri bolnikih, zdravljenih z repaglinidom, v primerjavi z bolniki, zdravljenimi z derivati sulfonilsečnine (glejte poglavji 4.4 in 4.8).
One event (angioedema) was considered serious and life-threatening, and the patient was discontinued from study treatment.
En neželeni učinek (angioedem) so smatrali za resen ter življenjsko ogrožajoč in bolniku so študijsko zdravilo ukinili.
One event was Grade 3; the remainder was Grade 2.
En dogodek je bil 3. stopnje; ostali dogodki so bili 2. stopnje.
One field study involved 230 dogs where Activyl Tick Plus was compared with fipronil (another ectoparasiticide), where the medicines were given every four weeks for 84 days.
Ena terenska študija je vključevala 230 psov, pri katerih so zdravilo Activyl Tick Plus primerjali s fipronilom (drugim ektoparaziticidom), pri čemer so zdravili dajali vsake štiri tedne v obdobju 84 dni.
One field study involved 485 dogs with flea and/or tick infestations that were treated once either with Vectra 3D or another spot-on product containing two other substances that control fleas and ticks, fipronil and (s)-methoprene.
V eno študijo na terenu je bilo vključenih 485 psov z infestacijami bolh, klopov ali obojega, ki so prejeli enkratni odmerek zdravila Vectra 3D ali drugega zdravila za kožni nanos, ki vsebuje dve drugi snovi za zatiranje bolh in klopov, tj. fipronil in (s)-metopren.
One film-coated tablet contains 10 mg of leflunomide.
Ena filmsko obložena tableta zdravila Leflunomid ratiopharm 10 mg filmsko obložene tablete vsebuje 10 mg leflunomida.
One film-coated tablet contains 10 mg of leflunomide.
Vsaka filmsko obložena tableta vsebuje 10 mg leflunomida.
One film-coated tablet contains 100 mg erlotinib (as erlotinib hydrochloride).
Ena filmsko obložena tableta vsebuje 100 mg erlotiniba (v obliki erlotinibijevega klorida).
One film-coated tablet contains 100 mg of leflunomide.
Vsaka filmsko obložena tableta vsebuje 100 mg leflunomida.
One film-coated tablet contains 145 mg of fenofibrate and 40 mg of simvastatin.
Ena filmsko obložena tableta vsebuje 145 mg fenofibrata in 40 mg simvastatina.
One film-coated tablet contains 150 mg erlotinib (as erlotinib hydrochloride).
Ena filmsko obložena tableta vsebuje 150 mg erlotiniba (v obliki erlotinibijevega klorida).
One film-coated tablet contains 20 mg afatinib (as dimaleate).
Ena filmsko obloženo tableta vsebuje 20 mg afatiniba (v obliki dimaleata).
One film-coated tablet contains 20 mg of leflunomide
Ena filmsko obložena tableta vsebuje 20 mg leflunomida.
One film-coated tablet contains 20 mg of leflunomide
Vsaka filmsko obložena tableta vsebuje 20 mg leflunomida.
One film-coated tablet contains 20 mg of leflunomide.
Ena filmsko obložena tableta zdravila Leflunomid ratiopharm 20 mg filmsko obložene tablete vsebuje 20 mg leflunomida.
One film-coated tablet contains 25 mg erlotinib (as erlotinib hydrochloride).
Ena filmsko obložena tableta vsebuje 25 mg erlotiniba (v obliki erlotinibijevega klorida).
One film-coated tablet contains 30 mg afatinib (as dimaleate).
Ena filmsko obloženo tableta vsebuje 30 mg afatiniba (v obliki dimaleata).
One film-coated tablet contains 40 mg afatinib (as dimaleate).
Ena filmsko obloženo tableta vsebuje 40 mg afatiniba (v obliki dimaleata).
One film-coated tablet contains 5 mg ivabradine (equivalent to 5.39 mg ivabradine as hydrochloride)
Ena filmsko obložena tableta vsebuje 5 mg ivabradina (kar ustreza 5,39 mg ivabradinijevega klorida).
One film-coated tablet contains 50 mg afatinib (as dimaleate).
Ena filmsko obloženo tableta vsebuje 50 mg afatiniba (v obliki dimaleata).
One film-coated tablet contains 50 mg of the active substance delamanid.
Ena filmsko obložena tableta vsebuje 50 mg zdravilne učinkovine delamanida.
One film-coated tablet contains 500 mg of saquinavir as saquinavir mesilate.
Ena filmsko obložena tableta vsebuje 500 mg sakvinavirja, v obliki sakvinavirjevega mesilata.
One film-coated tablet contains 7.5 mg ivabradine (equivalent to 8.085 mg ivabradine as hydrochloride)
Ena filmsko obložena tableta vsebuje 7,5 mg ivabradina (kar ustreza 8,085 mg ivabradinijevega klorida).
One formulation buffer glass vial, with 10 ml clear, colourless solution.
eno stekleno vialo s pufrom za pripravo formulacije z 10 ml bistre, brezbarvne raztopine eno reakcijsko stekleno vialo (prazno)
One further change was seen which was not statistically significant (p  0.05), but which did show a significant dose trend.
Opažena je bila še ena sprememba, katere pojavnost ni bila statistično značilna (p  0,05), bila pa je v precejšnji meri odvisna od odmerka zdravila.
One further injection must be given, at least 2 weeks before farrowing.
Naslednji odmerek cepimo vsaj 2 tedna pred prasitvijo.
One g gel contains 78 mg of 5-aminolaevulinic acid (as hydrochloride).
En gram gela vsebuje 78 mg 5-aminolevulinske kisline (v obliki klorida).
One GIST patient was enrolled at the 15 mg/m2 dose level with no evidence of benefit.
En bolnik z GIST je bil v študijo vključen pri odmerku 15 mg/m2 brez znakov koristi.
One glass vial containing Cayston is opened by tearing and flipping up the blue cap or lifting up the metal flap, the metal ring is removed by carefully pulling the flap (tweezers or small pliers may be used to remove the metal ring if necessary) and the grey rubber stopper removed.
Eno stekleno vialo, ki vsebuje zdravilo Cayston, odprite tako, da odtrgate in odstranite modro zaporko ali dvignete kovinski jeziček proč, previdno vlecite jeziček in tako odstranite kovinski obroček (po potrebi lahko za odstranitev kovinskega obročka uporabite pinceto ali majhne klešče), ter odstranite siv gumijast zamašek.
one glass vial of recombinant human hyaluronidase, and one glass vial of human normal immunoglobulin 10%.
eno stekleno vialo rekombinantne humane hialuronidaze in eno stekleno vialo humanega polispecifičnega imunoglobulina 10 %.
One graduation mark of syrup contains 0.31 mmol (or 7.09 mg) sodium.
Sirup ene graduacijske oznake vsebuje 0,31 mmol (ali 7,09 mg) natrija.
One graduation of the 2-ml oral syringe corresponds to 5 mg of d-alpha-tocopherol in the form of tocofersolan.
Ena označba na 2 ml brizgi za peroralno uporabo ustreza 5 mg d-alfa-tokoferola v obliki tokofersolana.
One gram (g) gel contains 78 mg of 5-aminolaevulinic acid (as hydrochloride).
En gram (g) gela vsebuje 78 mg 5-aminolevulinske kisline (v obliki klorida).
One gram contains:
En gram vsebuje:
One gram contains: Active substance: Meloxicam 50 mg Excipient:
En gram vsebuje: Zdravilna učinkovina: Meloksikam 50 mg Pomožna snov:
One gram of gel contains 1 mg methylparahydroxybenzoate (E218) and 55 mg propylene glycol.
En gram gela vsebuje 1 mg metilparahidroksibenzoata (E218) in 55 mg propilenglikola.
One gram of gel contains 3.3 mg of brimonidine.
En gram gela vsebuje 3,3 mg brimonidina.
One gram of Protopic 0.03% ointment contains 0.3 mg tacrolimus (as tacrolimus monohydrate).
En gram zdravila Protopic 0,03% vsebuje 0,3 mg takrolimusa (v obliki takrolimus monohidrata).
One gram of Protopic 0.1% ointment contains 1.0 mg tacrolimus (as tacrolimus monohydrate).
En gram zdravila Protopic 0,1% vsebuje 1,0 mg takrolimusa (v obliki takrolimus monohidrata).
One gram of Viread granules contains 33 mg of tenofovir disoproxil (as fumarate).
En gram zdravila Viread zrnca vsebuje 33 mg dizoproksiltenofovirata (v obliki dizoproksiltenofovirijevega fumarata).
One half of the release liner should be removed and the sticky side should be applied and pressed firmly to the skin.
Eno polovico zaščitne plasti odstranimo, lepljivo stran namestimo in močno pritisnemo na kožo.
one hand, pick up the open ampoule, insert the needle and draw up all of the solvent.
vzemite odprto ampulo ter vanjo vstavite iglo in potegnite iz nje ves vehikel.
One hard capsule contains 0.5 mg anagrelide (as anagrelide hydrochloride).
Ena trda kapsula vsebuje 0,5 mg anagrelida (v obliki anagrelidijevega klorida).
One hard capsule contains 117.08 mg lactose (as monohydrate).
Ena trda kapsula vsebuje 117,08 mg laktoze (v obliki monohidrata).
One hard capsule contains 150 mg nilotinib (as hydrochloride monohydrate).
Ena trda kapsula vsebuje 150 mg nilotiniba (v obliki hidroklorid monohidrata).
One hard capsule contains 156.11 mg lactose (as monohydrate).
Ena trda kapsula vsebuje 156,11 mg laktoze (v obliki monohidrata).
One hard capsule contains 200 mg nilotinib (as hydrochloride monohydrate).
Ena trda kapsula vsebuje 200 mg nilotiniba (v obliki hidroklorid monohidrata).
One hard capsule contains cabozantinib (S)-malate equivalent to 20 mg cabozantinib.
Ena trda kapsula vsebuje kabozantinib (S)-malat v količini, ki ustreza 20 mg kabozantiniba.
One HDPE bottle with child resistant closure and sealing disk, containing 30 tablets and one silica gel desiccant sachet, packed within a cardbox.
Steklenička (HDPE) zaprta z zamaškom, ki preprečuje otrokom odpiranje in zaščitnim pokrovom; v steklenički je 30 tablet in vrečica s silica gelom.
one human insulin preparation to another, a regimen with only regular insulin to one with a longer-acting insulin.
pripravka enega humanega insulina na drugega, s sheme z le enim navadnim insulinom na shemo z dolgodelujočim insulinom.
One hundred and five patients were randomised to 5-FU/FA + placebo arm and 104 patients to 5-FU/FA + Avastin (5 mg/kg every 2 weeks) arm.
Randomiziranih je bilo 105 bolnikov, ki so prejeli 5-FU/FA + placebo, in 104 bolniki, ki so prejeli 5-FU/FA  Avastin (5 mg/kg vsaka dva tedna).
One hundred and ninety had at least 1 evaluable time point response and were included in the analysis (table 3).
Stodevetdeset jih je imelo vsaj 1 ocenljivo časovno točko odziva in so bili vključeni v analizo (tabela 3).
One hundred and six patients received at least one 50 mg dose of sunitinib on schedule 4/2.
Sto šest bolnikov je dobilo vsaj en 50 mg odmerek sunitiniba po shemi 4/2.
One hundred and thirty patients (≥ 18 years of age) with multiple myeloma who previously had at least partial response on a bortezomib -containing regimen were retreated upon progression.
Bolnike, ki so predhodno imeli vsaj delni odgovor na režim zdravljenja z bortezomibom so ponovno zdravili po napredovanju bolezni.
One hundred and twenty (70%) patients in the chemotherapy arm received subsequent crizotinib treatment.
Poznejše zdravljenje s krizotinibom je prejelo 120 (70 %) bolnikov v skupini s kemoterapijo.
One hundred and twenty-nine (129) new malignancies of various types were observed in 4,114 rheumatoid arthritis patients treated in clinical trials with Enbrel for up to approximately 6 years, including 231 patients treated with Enbrel in combination with methotrexate in the 2-year active-controlled study.
Sto devetindvajset (129) novih malignih obolenj različnih tipov so ugotovili pri 4.114 bolnikih z revmatoidnim artritisom, zdravljenih v kliničnih preskušanjih z zdravilom Enbrel do približno 6 let, vključno z 231 bolniki, ki so bili zdravljeni s kombinacijo zdravila Enbrel in metotreksata v dvoletni študiji, nadzorovani z zdravilno učinkovino.
One hundred and twenty-nine (129) new malignancies of various types were observed in 4,114 rheumatoid arthritis patients treated in clinical trials with etanercept for up to approximately 6 years, including 231 patients treated with etanercept in combination with methotrexate in the 2-year active- controlled study.
Sto devetindvajset (129) novih malignih obolenj različnih tipov so ugotovili pri 4.114 bolnikih z revmatoidnim artritisom, zdravljenih v kliničnih preskušanjih z etanerceptom do približno 6 let, vključno z 231 bolniki, ki so bili zdravljeni s kombinacijo etanercepta in metotreksata v dvoletni študiji, nadzorovani z zdravilno učinkovino.
One hundred eighty six patients were randomized to receive docetaxel (100 mg/m2) with or without trastuzumab; 60% of patients received prior anthracycline-based adjuvant chemotherapy.
186 bolnic so randomizirali na dobivanje docetaksela (100 mg/m2) s trastuzumabom ali brez njega; 60 % bolnic je prej dobilo adjuvantno kemoterapijo na osnovi antraciklinov.
One hundred eighty six patients were randomized to receive docetaxel (100 mg/m2) with or without trastuzumab; 60% of patients received prior anthracycline-based adjuvant chemotherapy.
Stošestinosemdeset (186) bolnic je bilo randomiziranih na prejemanjedocetaksel (100 mg/m2) s trastuzumabom ali brez njega; 60 % bolnic je prej dobilo adjuvantno kemoterapijo na osnovi antraciklinov.
One hundred forty-one and 139 adult subjects were randomised to a tenofovir disoproxil fumarate and emtricitabine plus tenofovir disoproxil fumarate treatment arm, respectively.
141 odraslih bolnikov je bilo randomiziranih v skupino z dizoproksiltenofovirijevim fumaratom in 139 odraslih bolnikov v skupino z emtricitabinom in dizoproksiltenofovirijevim fumaratom.
One hundred patients (n=100) from the Paediatric CD Study continued in an open-label long-term extension study.
Sto bolnikov (n=100) iz študije Chronove bolezni pri pediatričnih bolnikih je nadaljevalo v odprti dolgoročni podaljšani študiji.
One hundred patients then entered the second part of the study, which compared Ilaris with placebo.
Sto bolnikov je nato sodelovalo v drugem delu študije, v katerem so zdravilo Ilaris primerjali s placebom.
One Hypodermic syringe and safety needle (Hypodermic Device)
Eno podkožno injekcijsko brizgo in varnostno iglo (podkožna naprava)
One ibritumomab tiuxetan glass vial, with 2 ml clear, colourless solution.
eno stekleno vialo z ibritumomab tiuksetanom z 2 ml bistre, brezbarvne raztopine
One Ilaris injection kit contains 1 vial of powder for solution for injection, 1 vial of solvent,1 injection syringe of 1 ml, 1 safety needle, 2 vial adapters and 4 cleansing swabs.
En komplet za injiciranje zdravila Ilaris vsebuje 1 vialo s praškom za raztopino za injiciranje, 1 vialo z vehiklom, 1 injekcijsko brizgo 1 ml, 1 varnostno iglo, 2 adapterja za vialo in 4 čistilne blazinice.
One implant contains 700 micrograms of dexamethasone
En vsadek vsebuje 700 mikrogramov deksametazona.
One implant preloaded in one implanter
En implantat, napolnjen v enem implantatorju.
One implant preloaded in one implanter.
En implantat, napolnjen v enem implantatorju.
One individual blister should be teared off from the blister card along the perforated line.
Po perforaciji odtrgajte eno enoto s pretisnega omota.
One individual treatment dose in 50-500 mL ethylene-vinyl-acetate cryo bag, inside a plastic bag and then a metal box.
En odmerek za individualno zdravljenje v 50- do 500-ml zamrzovalni vreči iz etilen-vinil-acetata v plastični vreči in nato v kovinski škatli.
One inhalation of Relvar Ellipta 184/22 micrograms once daily.
Ena inhalacija zdravila Relvar Ellipta 184/22 mikrogramov enkrat na dan.
One inhalation of Revinty Ellipta 184/22 micrograms once daily.
Ena inhalacija zdravila Revinty Ellipta 184/22 mikrogramov enkrat na dan.
One inhalation session with Breelib will usually last about 3 minutes.
Posamezna inhalacija nebulatorjem Breelib običajno traja 3 minute.
One inhalation twice a day
en vdih dvakrat na dan
One injection at each gestation, at least 2 to 4 weeks before farrowing.
Ena injekcija v vsakem obdobju brejosti, vsaj 2 do 4 tedne pred prasitvijo.
One injection from 3 weeks of age.
Ena injekcija od 3. tedna starosti.
One injection is sufficient to carry out the scan that your doctor needs.
Eno injiciranje je dovolj, da se lahko opravi slikanje, ki ga potrebuje vaš zdravnik.
One injection is usually enough to treat an attack, but a second injection may be given if the patient does not improve enough after the first one.
Ena injekcija navadno zadošča za zdravljenje napada, vendar se lahko vbrizga drugi odmerek, če se stanje po prvi injekciji ne izboljša dovolj.
One injection of Avonex, once a week.
Ena injekcija zdravila Avonex enkrat na teden.
One injection using Avonex Pen, once a week.
Ena injekcija z napolnjenim injekcijskim peresnikom Avonex Pen enkrat na teden.
One International Unit (IU) of factor IX activity is equivalent to that quantity of factor IX in one ml of normal human plasma.
Ena mednarodna enota (i.e.) aktivnosti faktorja IX ustreza količini faktorja IX v enem ml normalne človeške plazme.
One International Unit (IU) of factor IX activity is related to the quantity of factor IX in the International Standard for factor II, VII, IX and X in human plasma (approved by the WHO) which approximates to the quantity of factor IX in one ml of normal human plasma.
Ena mednarodna enota (i.e.) aktivnosti faktorja IX je povezana s količino faktorja IX v Mednarodnem standardu za faktor II, VII, IX in X v človeški plazmi (odobrila WHO), ki je približek količini faktorja IX v enem ml normalne človeške plazme.
One intravenous injection of 4200 U (two vials).
Ena intravenska injekcija 4200 e. (dve viali).
One intravenous injection of 50 U/kg body weight.
Ena intravenska injekcija 50 e./kg telesne mase.
one is given as an infusion into a vein (intravenous infusion) the other is given as an injection under the skin (subcutaneous injection) using a manual syringe or the administration system.
ena se daje kot infuzija v veno (intravenska infuzija), druga se daje kot injekcija pod kožo (subkutana ali podkožna injekcija), pri čemer lahko uporabimo injekcijsko brizgo ali aplikacijski sistem.